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Abstract
           
               In up to 10% of patients who present with ventricular tachycardia (VT), obvious 
structural heart disease is not identified. In such patients, causes of ventricular arrhythmia 
include right ventricular outflow tract (RVOT) VT, extrasystoles, idiopathic left ventricular 
tachycardia   (ILVT),   idiopathic   propranolol-sensitive   VT   (IPVT),   catecholaminergic 
polymorphic VT (CPVT), Brugada syndrome, and long QT syndrome (LQTS). RVOT VT, 
ILVT, and IPVT are referred to as idiopathic VT and generally do not have a familial basis. 
RVOT VT and ILVT are monomorphic, whereas IPVT may be monomorphic or polymorphic. 
The idiopathic VTs are classified by the ventricle of origin, the response to pharmacologic 
agents, catecholamine dependence, and the specific morphologic features of the arrhythmia. 
CPVT, Brugada syndrome, and LQTS are inherited ion channelopathies. CPVT may present as 
bidirectional VT, polymorphic VT, or catecholaminergic ventricular fibrillation. Syncope and 
sudden death in Brugada syndrome are usually due to polymorphic VT. The characteristic 
arrhythmia of LQTS is torsades de pointes. Overall, patients with idiopathic VT have a better 
prognosis than do patients with ventricular arrhythmias and structural heart disease. Initial 
treatment approach is pharmacologic and radiofrequency ablation is curative in most patients. 
However,   radiofrequency   ablation   is   not   useful   in   the   management   of   inherited   ion 
channelopathies. Prognosis for patients with VT secondary to ion channelopathies is variable. 
High-risk patients (recurrent syncope and sudden cardiac death survivors) with inherited ion 
channelopathies   benefit  from  implantable  cardioverter-defibrillator   placement.   This   paper 
reviews the mechanism, clinical presentation, and management of VT in the absence of 
structural heart disease.                                                                                                         
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Abbreviations
ARVD, arrhythmogenic right ventricular dysplasia                                                     
cAMP,   cyclic   adenosine   monophosphate                                                      
CPVT, catecholaminergic polymorphic ventricular tachycardia                     
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ECG,   electrocardiogram                                                              
ICD,   implantable cardioverter-defibrillator                                                                       
ILVT, idiopathic left ventricular tachycardia                                                                 
IPVT,  idiopathic propranolol-sensitive (automatic) ventricular tachycardia                        
LBBB, left bundle branch block                                                                 
LQTS, long QT syndrome LV, left ventricle                                                                             
LVOT, left ventricular outflow tract                                                             
MRI,   magnetic   resonance   imaging                                      
RBBB, right bundle branch block                                                                                                       
RF,   radiofrequency                                
RV,   right   ventricle                                    
RVOT, right ventricular outflow tract                                                                
RyR2,   ryanodine   receptor                                                                   2  
VT,       ventricular tachycardia
Introduction
            It is estimated that 10% of patients who present with ventricular tachycardia (VT) have 
no obvious structural heart disease.1 An absence of structural heart disease is usually suggested 
if an electrocardiogram (ECG) (except in Brugada syndrome and long QT syndrome [LQTS]), 
echocardiogram,   and   coronary   arteriogram   collectively   are   normal.2  However,   structural 
abnormalities may be identified by magnetic resonance imaging (MRI) even if all other test 
results are normal.3  In addition, focal dysautonomia in the form of localized sympathetic 
denervation has been reported in patients with VT and no other obvious structural heart disease.4
        Types of VT that occur in the absence of structural heart disease include right ventricular 
(RV) monomorphic extrasystoles, RV outflow tract (RVOT) VT, left ventricular (LV) outflow 
tract   (LVOT)   VT,   idiopathic   LV   tachycardia   (ILVT),   idiopathic   propranolol-sensitive 
(automatic) VT (IPVT), catecholaminergic polymorphic VT (CPVT), Brugada syndrome, and 
LQTS. RV monomorphic extrasystoles, RVOT VT, LVOT VT, ILVT, and IPVT are referred to 
as idiopathic VT. Idiopathic VT from the RVOT and LV are monomorphic and generally not 
familial. Idiopathic VTs are classified with respect to the ventricle of origin, the response to 
pharmacologic agents, evidence of catecholamine dependence, and the specific morphologic 
features (QRS morphology, axis, pattern, and whether tachycardia is repetitive, nonsustained, or 
sustained) (Table 1). CPVT, Brugada syndrome, and LQTS are inherited ion channelopathies. 
            In this review of VT in the absence of structural heart disease, we discuss the clinical 
recognition and management of idiopathic VT and inherited ion channelopathies. The articles 
were selected for review from a search of PubMed using search terms “idiopathic VT,” 
“LQTS,” “Brugada syndrome,” and “CPVT.” For each topic, articles focusing on diagnosis and 
management were preferentially selected.                                                                                   
RV Monomorphic Extrasystoles and RVOT VT                                           
            RV monomorphic extrasystoles and RVOT VT appear to be on a continuum of the same 
process. RV monomorphic extrasystoles are characterized by ventricular ectopy with left bundle 
branch  block  (LBBB)   morphology,  and,  on  ECG,   the  QRS   axis  is  directed  inferiorly. 
Ventricular ectopy of this type was defined in 1969 and considered “typical for normal 
subjects.”5 Resting ECG in these patients has no identifiable abnormalities, and the prognosis is 
generally benign. These extrasystoles occur more often during the day than at night and are 
transiently suppressed by sinus tachycardia.6 The extrasystoles may diminish or disappear with 
exercise during stress testing. The site of origin is most often the RVOT and, to a lesser extent, 
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the interventricular septum in the region of the RVOT.7 An echocardiogram is normal in most of 
these patients,8 although anatomic changes, such as focal thinning and fatty replacement of the 
RVOT, have been demonstrated with MRI.3 
Table 1. Types of Idiopathic Ventricular Tachycardia
ILVT,   idiopathic   left   ventricular   tachycardia;   IPVT,   idiopathic   propanolol-
sensitive ventricular tachycardia; LBBB, left bundle branch block; LVOT, left 
ventricular outflow tract; RBBB, right bundle branch block; RF, radiofrequency; 
RVOT, right ventricular outflow tract; VT, ventricular tachycardia.
            A potential relationship between these seemingly benign ventricular extrasystoles of 
RVOT origin and structural cardiac disease (arrhythmogenic RV dysplasia [ARVD]) has been 
investigated.9 Sixty-one patients with RVOT ventricular extrasystoles were contacted 15 years 
after their initial visit; no patient had died of sudden death nor developed ARVD in this study. 
Two-thirds of the patients were asymptomatic, and, in half, the ventricular ectopy had 
disappeared. Focal fatty replacement of the RV was present on MRI in most patients, in contrast 
to   the   diffuse   pattern   of   fatty   replacement   observed   in   patients   with   ARVD.  
            In North America, 70% of cases of idiopathic VT arise from the RV, chiefly the RVOT 
just inferior to the pulmonic valve.2 The characteristic morphology of RVOT VT is a wide QRS 
complex tachycardia with LBBB pattern and an inferior axis.10  Among the outflow tract 
tachycardias, 90% originate from the RVOT and 10% from the LVOT. Either or both forms may 
be found in the same patient. RVOT VT is usually diagnosed in the third to fifth decade of life, 
although cases at the extremes of age have been reported. Most patients (80%) present with 
palpitations or presyncope (50%) but rarely present with frank syncope. Exercise or emotional 
stress usually precipitates the tachycardia. Sudden death is rare. 
            Two phenotypic forms of RVOT VT occur: nonsustained, repetitive, monomorphic VT 
(Fig. 1)11 and paroxysmal, exercise-induced, sustained VT (Fig. 2). Both are terminated by the 
administration of adenosine. Specific ECG characteristics have been described to differentiate 
RVOT VT from LVOT VT.12 LVOT VT may originate from either the supravalvular region of a 
coronary cusp or the infravalvular endocardial region of a coronary cusp of the aortic valve. The 
distinction between supravalvular and infravalvular location of the tachycardia has important 
therapeutic implications, particularly if radiofrequency (RF) ablation is performed. LVOT VT is 
suggested if the ECG during VT shows an S wave in lead I and an R-wave transition in lead V1 
or V2. The absence of an S wave in V5 or V6 suggests a supravalvular location, whereas an 
S  wave in leads V5 and V6 indicates an infravalvular location (Fig. 3). In addition, in 
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leadsV1 and V2, an R:S amplitude ratio of 30% or more or an R:QRS duration ratio of 50% or 
more  suggests   an   LV   (aortic   sinus   cusp)   origin   of   the   tachycardia.13  
    
Fig. 1. Electrocardiogram illustrating repetitive monomorphic right ventricular outflow tract 
ventricular tachycardia, left bundle branch block morphology, and an inferior axis.
Fig. 2. Electrocardiogram illustrating sustained right ventricular outflow tract ventricular 
tachycardia, left bundle branch block morphology, and an inferior axis.
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Fig. 3.  Electrocardiogram illustrating left ventricular outflow tract ventricular 
tachycardia (LVOT VT). The S wave in LI and R-wave transition in V1 suggest 
LVOT VT. In addition, an R:S amplitude ratio of 30% and an R:QRS duration 
ratio of 50% are seen. Presence of an S wave in leads V5 and V6 suggests an 
infravalvular origin of the tachycardia.
            Exercise stress testing is used frequently to initiate and evaluate RVOT VT (unlike RV 
monomorphic extrasystoles, which are suppressed by sinus tachycardia) but is not clinically 
helpful in most cases. Initiation of the tachycardia depends on a critical heart rate that differs in 
each patient. The VT may be initiated during exercise or recovery.14 ECG and echocardiogram 
in sinus rhythm are usually normal, as is coronary angiography. MRI may show abnormalities of 
the RV in up to 70% of patients, including focal thinning, diminished systolic wall thickening, 
and abnormal wall motion.15                                                                                                      
            RVOT VT should be distinguished from ARVD, a disorder with a more serious clinical 
outcome. The VT in ARVD may have morphologic features similar to RVOT VT (LBBB with 
inferior axis) but does not terminate with adenosine. In ARVD, the resting 12-lead ECG 
typically shows inverted T waves in right precordial leads. When present, RV conduction delay 
with an epsilon wave (Fig. 4), best seen in leads V1-V2, is helpful in the diagnosis of ARVD. 
Measurement of serum brain natriuretic peptide may help distinguish ARVD from RVOT VT.16 
The level of brain natriuretic peptide is increased in ARVD, most likely due to increased 
expression by the surviving myocytes surrounded by atrophic tissue, which is indicative of the 
severity of RV dysfunction. Mechanisms of ARVD-related VT include both reentry facilitated 
by slow conduction through areas of fatty infiltration and increased automaticity.17 In ARVD, 
the areas typically affected on echocardiography or MRI include the apex, interventricular 
septum below the tricuspid septal leaflet, and the RVOT. In some cases, fatty infiltration of the 
LV occurs. An RV biopsy and histopathologic characterization may help determine the correct 
diagnosis. 
               The differential diagnosis of RVOT VT also includes tachycardias associated with 
atriofascicular fibers (Mahaim fibers), atrioventricular reentrant tachycardia using a right-sided 
accessory pathway, and VT occurring in patients after repair of tetralogy of Fallot. 
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Fig. 4. Electrocardiogram showing an epsilon wave (arrow) in a patient with arrhythmogenic 
right ventricular dysplasia.
              
Mechanism   of   RVOT   VT                                                                                
            Intracellular calcium overload appears to be the principal underlying mechanism of 
RVOT VT. Cytosolic calcium overload enhances the function of the Na+/Ca2+ exchanger, which 
leads to increasing inward current and delayed afterdepolarization. When the inward current is 
of sufficient threshold, the delayed afterdepolarization may cause another action potential and 
initiate  tachycardia.   Cyclic  adenosine  monophosphate   (cAMP)   has   a  substantial  role  in 
regulating intracellular calcium. When the concentration of cAMP is increased, intracellular 
calcium levels are high. Adenosine is effective in terminating RVOT VT because of its ability to 
lower cAMP concentration.18 Beta-blockers are often effective because of their inhibition of 
adenylate cyclase, which leads to a decrease of cAMP. Verapamil inhibits L-type calcium 
channels, which decreases the concentration of intracellular calcium and thereby has salutary 
effects.
            Triggered activity, rather than reentry or enhanced automaticity, as the cause of RVOT 
VT is evidenced by termination with administration of adenosine and inability to entrain. The 
tachycardia may be inducible by programmed extrastimuli or by burst pacing the ventricle or 
atrium or by infusion of isoproterenol. Somatic mutation involving the G-protein signaling 
cascade could give rise to RVOT VT by disrupting adenosine signaling. Of interest, mutation of 
the G protein subunit Alphai2 has been identified on myocardial biopsy in only the RVOT (the 
site of origin) and not in myocardium remote from the site of VT.19                                     
Treatment   of   RVOT   VT                                                                          
            Acute termination of RVOT VT can be achieved by vagal maneuver or intravenous 
administration of adenosine, 6 mg, which can be titrated up to 24 mg as needed. Intravenous 
verapamil, 10 mg, given over 1 minute is an alternative, provided the patient has adequate blood 
pressure and has a previously established diagnosis of verapamil-sensitive VT. Lidocaine also 
may be effective in some cases. Hemodynamic instability warrants emergent cardioversion.
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 5(2): 106-121 (2005)Komandoor Srivathsan, Steven J. Lester, Christopher P. Appleton, Luis R. P. Scott, 112 
Thomas M. Munger, “Ventricular Tachycardia in the Absence of Structural Heart Disease”
            Long-term treatment options for RVOT VT include medical therapy or RF ablation. 
Medications, including beta-blockers or verapamil (diltiazem is equally effective), have a 25% 
to 50% rate of efficacy.20 Alternative therapy includes class IA, class IC, and class III agents 
including amiodarone.20 RF ablation now has cure rates of 90%,10 which makes it a preferable 
option, given the young age of patients with RVOT VT. Ablation of sites at the aortic sinus cusp 
has been successful for treatment of LVOT VT,13  but serious complications may occur, 
including left main coronary artery occlusion. Coronary arteriography before and during 
ablation is recommended to keep the tip of the ablation catheter 1 cm away from the ostia of the 
coronary arteries. After ablation, arteriography should be repeated to assess the patency of 
coronary   arteries.   Epicardial   foci   of   the   LVOT   remain   a   challenging   ablation   target.
ILVT
               Most   VTs   of   LV   origin   are   verapamil-sensitive   intrafascicular   tachycardias. 
Intrafascicular tachycardia has a right bundle branch block (RBBB) left-axis configuration in 
90% to 95% of cases (exit site, left posterior fascicle) and the rest have RBBB with a right-axis 
pattern (exit site, left anterior fascicle). This form of VT is seen in the second to fourth decade 
of life and occurs more often in men (60%-80%).21  Symptoms during tachycardia include 
palpitations, dizziness, presyncope, and syncope. Sudden death is usually not seen, but one 
possible   case   has   been   reported.22                                                                           
            A proposed diagnostic triad of ILVT includes: 1) induction with atrial pacing, 2) RBBB 
with left axis configuration, and 3) no evidence of structural heart disease.23 A fourth feature, 
verapamil sensitivity, has since been described.24                                                                       
Mechanism of ILVT                                                                                                         
            Focal reentry appears to be the principal mechanism of ILVT. The tachycardia cycle 
length can be increased with the administration of verapamil.25 Some evidence implicates the 
Purkinje fibers of the fascicle as the area of slow conduction because of the presence of high-
frequency potentials (Purkinje potentials).26 Others have found late diastolic potentials near the 
main trunk of the left bundle branch. Another hypothesis implicates a false tendon extending 
from the inferoposterior aspect of the LV to the basal septum as directly or indirectly having a 
role in causing this arrhythmia.27                                                                                                  
Treatment of ILVT                                                                                                                       
            In the acute setting, this tachycardia responds to intravenous verapamil. Termination 
with adenosine is rare, except for cases in which isoproterenol is used for induction of the 
tachycardia. Long-term therapy with verapamil is useful in mild cases and RF ablation is highly 
effective (85%-90%) in those with severe symptoms.21 Identifying the focus of ablation may 
involve   recognition   of   Purkinje  potential,   late  diastolic   potential,   or   earliest   ventricular 
activation. Electroanatomic mapping may help localize the area of slow conduction.28 In about 
10% of cases of both ILVT and RVOT VT, a tachycardia with a different morphology may be 
inducible after successful ablation of clinical VT. This second tachycardia may be a cause for 
recurrence and should preferably be ablated during the initial attempt.29                                               
IPVT
            This form of idiopathic VT usually occurs by the fifth decade of life and can arise from 
the LV or RV.21 The morphology of the tachycardia may be monomorphic or polymorphic. 
IPVT is not inducible with programmed stimulation. Isoproterenol infusion usually induces this 
VT. Beta-blockers are effective in terminating the tachycardia.                               
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Treatment of IPVT                                                                                                 
            Beta-blockers are used to treat this form of VT because they are effective in acute 
situations. There is insufficient information available regarding long-term management of IPVT. 
Survivors of sudden cardiac death may receive an implantable cardioverter-defibrillator (ICD). 
Inherited Channelopathies                                                                                                 
CPVT
            CPVT is characterized by a uniform pattern of bidirectional polymorphic VT that can be 
easily and reproducibly induced during exercise or catecholamine infusion. A third of patients 
with CPVT have a family history of premature sudden death or stress-related syncope.30 
Exercise or acute emotion usually triggers syncope. Symptoms typically manifest in childhood; 
onset   in   adulthood   has   been   reported   but   is   uncommon.  
            The ryanodine receptor 2 (RyR2) is important for the regulation of intracellular calcium 
fluxes.31  In patients with CPVT, the RyR2 gene is mutated, with autosomal dominant 
inheritance suggested.32  One family with recessive CPVT has been reported, and the gene 
responsible produces the protein calsequestrin, which is functionally related to RyR2.33 
            CPVT and IPVT can be distinguished by means of family history, morphology (CPVT is 
usually bidirectional), age of onset (childhood vs the fifth decade), and in some cases genetic 
testing (genetic defect vs idiopathic).                                                                       
Treatment
            Beta-blockers are the preferred therapy for CPVT.30  Beta-blockers may prevent syncope 
and sudden death because adrenergic activation is the main mechanism of delayed after 
depolarization-dependent triggered activity in these patients.34 An ICD is required in 30% of 
patients because of symptomatic recurrence of life-threatening arrhythmia in spite of beta-
blocker   therapy.35                                                                                                    
Brugada   Syndrome                                                                                
            Brugada syndrome is characterized by apparent RBBB with ST elevation in V1 to V3 
(V2 always present) (Fig. 5), life-threatening cardiac arrhythmia (polymorphic VT) with no 
demonstrable structural cardiac disease, and familial occurrence.36,37 The ECG changes may 
mimic acute myocardial infarction. The ECG findings may not be evident on resting 12-lead 
ECG but may be unmasked by flecainide or procainamide.38,39  Two different types of ST 
elevation have been described: coved and saddleback. The coved type is more relevant to the 
syndrome than is the saddleback type.40 Genetic analysis indicates that Brugada syndrome is due 
to mutation of the SCN5A protein.41 The incidence of the disease is about 5 per 10,000 persons. 
The Brugada-type ECG (“Brugada sign”) may be much more common than is the clinical 
syndrome.42 Sudden death is usually due to polymorphic VT or ventricular fibrillation. The 
disease predominantly affects young males. 
            The risk of sudden cardiac death with Brugada syndrome is substantial. In a study of 334 
patients with typical Brugada-type ECG findings, which included symptomatic (cardiac arrest 
and syncope) and asymptomatic patients, the risk of recurrent events during 4 years of follow-up 
was 62% for those with cardiac arrest and 19% for those with syncope.37 The asymptomatic 
group had an 8% event rate during 2 years of follow-up.
Management
               ICD placement is the treatment of choice in symptomatic patients. Asymptomatic 
patients   with   Brugada-type   ECG   results   should   undergo   electrophysiologic   testing   .   If 
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ventricular arrhythmia is inducible (two-thirds of patients are noninducible) the patient should 
receive an ICD. Asymptomatic patients with normal baseline ECG do not require further testing.
Fig. 5. Electrocardiogram of a patient with Brugada syndrome. The right bundle 
branch block pattern with coved ST segment elevation (J-point elevation) is more 
than 2 mm, particularly in lead V2.
LQTS
            LQTS is an uncommon disorder in the general population. It is an inherited disorder, and 
mutations in 7 genes for LQTS have been identified to date (Table 2).43 This syndrome was 
initially identified in a family in which several children had syncope and  sudden death. A 
recessive inheritance pattern was identified, and the syndrome was associated with deafness 
(Jervell and Lange-Nielsen syndrome). A similar and more common disorder without deafness, 
inherited in an autosomal dominant pattern, was subsequently identified (Romano-Ward 
syndrome).
Clinical Diagnosis
            Syncope, sudden cardiac death, or family screening of an affected individual is the 
reason that physicians evaluate patients for LQTS. Prolonged QT interval on ECG makes a 
diagnosis of LQTS likely. Medications that prolong QT interval must be carefully excluded 
from the patient’s medication list. Family history may be helpful for diagnosis of LQTS. An 
incidental finding of prolonged QTc (not due to medications) in an asymptomatic person is rare. 
Syncope and sudden death with LQTS occur with higher frequency during adolescence.
Triggers of Clinical Events
            In patients with LQT1 subtype, exercise seems to precipitate clinical events.44 In those 
with LQT2, acute arousal, such as a sudden loud noise, tends to be a precipitating factor. In 
patients with LQT3, clinical events occur at rest or during sleep.
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Table 2. Genetic Subtypes of Long QT Syndrome*
IKir2.1, inward rectifier K+ current; IKr, rapid delayed rectifier K+ current; IKs, 
slow   delayed   rectifier   K+  current;   LQTS,   long   QT   syndrome.
*Includes LQT1-LQT7 of autosomal dominant inheritance and Romano-Ward 
syndrome.
†Homozygous mutations result in Jervell and Lange-Nielsen syndrome.
Clinical Course
            The risk of cardiac events is higher with certain genotypes; patients with LQT1 and 
LQT2 have higher risk of events than do those with LQT3.45 The risk of events also is higher 
during adulthood in females and during adolescence (before puberty) in males. The length of the 
QTc interval and the number of mutations also increase the risk. Once a clinical event occurs 
(syncope   or   survival   after   sudden   cardiac   death),   recurrence   is   frequent.  
ECG Findings
            Eighty percent of LQT1 and LQT2 carriers and 65% of LQT3 carriers have typical 
ECGs. In LQT1, the T wave is broad-based with an indistinct onset. In LQT2, bifid T waves 
may be seen in all 12 leads, and the ECG in LQT3 may have a long isoelectric ST segment.46
Treatment
               Adrenergic   modulation  with  beta-blockers   is   the  most   useful  therapy  in  both 
symptomatic and asymptomatic patients, even though beta-blockers do not alter QTc interval.47 
However, the benefits of beta-blockers have not been proven in a randomized trial. Surgical 
sympathectomy is an adjuvant treatment and has been done rarely since the introduction of beta-
blockers. Oral potassium may be useful in certain genotypes.48 ICD placement, along with beta-
blocker therapy, offers the best protection in high-risk patients (survivors of sudden death and 
those with recurrent syncope).49
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Acquired LQTS and Torsades de Pointes
            Acquired prolongation of QT interval and pause-dependent, early afterdepolarization-
mediated torsades de pointes most often is caused by medication and occasionally is caused by 
metabolic   derangement   (hypokalemia   and   hypomagnesemia).50  Correction   of   electrolyte 
abnormalities and discontinuation of precipitating drugs usually lead to amelioration of the 
arrhythmia. Intravenous magnesium, although it may not have an effect on QT interval, is highly 
effective at suppressing torsades de pointes. Occasionally, a temporary transvenous pacemaker 
or isoprenaline may be needed for effective management.
Diagnostic Approach to Ventricular Arrhythmia in the Absence of Structural Heart 
Disease
    
            The approach to diagnosis of the subtypes of VT in the absence of heart disease depends 
on the morphology of the tachycardia precipitating the clinical event. If the presentation is 
monomorphic VT, RVOT VT, LVOT VT, ILVT, and, rarely, IPVT are in the differential 
diagnosis. Specific ECG criteria should help clarify the diagnosis (Fig. 6). If the inciting clinical 
event is precipitated by polymorphic VT, torsades de pointes, or ventricular fibrillation, the 
diagnosis may be approached by evaluating the baseline or postresuscitation QTc interval 
(without antiarrhythmic medications) (Fig. 7). If the QTc is prolonged, LQTS and its subtypes 
are  the  predominant  diagnoses,  provided  drug-induced  Qtc  prolongation  can  be reasonably 
Fig. 6. Diagnostic scheme for monomorphic ventricular tachycardia in structurally 
normal   hearts   (collectively   normal   electrocardiogram,   echocardiogram,   and 
coronary angiogram). ILVT, idiopathic left ventricular tachycardia; LBBB, left 
bundle branch block; LVOT, left ventricular outflow tract; RBBB, right bundle 
branch block; RVOT, right ventricular outflow tract; VT, ventricular tachycardia.
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excluded. If the QTc is normal, Brugada syndrome, CPVT, and IPVT are the conditions in the 
differential diagnosis. The Brugada ECG, either at baseline or on induction with antiarrhythmic 
medication, may help identify Brugada syndrome. Bidirectional VT and presentation during 
childhood identify most patients with CPVT. IPVT remains a diagnosis when all other causes 
are unlikely and the arrhythmia is propranolol sensitive. Genetic testing may be helpful in the 
long-term evaluation of polymorphic VT but acutely is not helpful.
Fig. 7. Proposed diagnostic scheme for polymorphic VT or ventricular fibrillation 
in structurally normal hearts (collectively normal electrocardiogram [except in 
Brugada  syndrome  and  LQTS],  echocardiogram,   and  coronary   angiogram). 
CPVT,   catecholaminergic   polymorphic   ventricular   tachycardia;   ECG, 
electrocardiogram; IPVT, idiopathic propranolol-sensitive (automatic) ventricular 
tachycardia; LQTS, long QT syndrome; VT, ventricular tachycardia.
Conclusion
            Ventricular arrhythmia in the absence of structural heart disease is a small subset in the 
clinical spectrum of patients with VT. Overall, the prognosis is better in patients with idiopathic 
ventricular arrhythmia than in patients with structural heart disease and VT. Prognosis in 
hereditary channelopathies is variable; CPVT, in particular, has a malignant course when 
untreated. Understanding the different characteristics of these tachycardias, their diagnostic 
features, and physiologic substrates is essential for successful therapy and management. Stress 
testing and response to antiarrhythmics each have an important role in identifying the specific 
arrhythmia. RF ablation and placement of an ICD are important in the overall management of 
specific arrhythmia.
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